3-ethyl-4-methyl-anisole | 6161-68-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-ethyl-4-methyl-anisole
• 英文别名: Methyl-(4-methyl-3-aethyl-phenyl)-aether；4-Methoxy-1-methyl-2-aethyl-benzol；3-Aethyl-4-methyl-anisol；2-Ethyl-4-methoxy-1-methylbenzene
• CAS: 6161-68-8
• 化学式: C₁₀H₁₄O
• 分子量: 150.221
• InChiKey: IYQVEBDUUXLMNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-ethyl-4-methyl-anisole 生成 3-ethyl-4-methyl-cyclohex-2-enone
  参考文献：
  名称：

  Pons,A. et al., Bulletin de la Societe Chimique de France, 1979, vol. , p. 381 - 387

  摘要：

  DOI：
• 作为产物：
  描述：

  硫酸二乙酯 、 alkaline earth salt of/the/ methylsulfuric acid 生成 3-ethyl-4-methyl-anisole
  参考文献：
  名称：

  89.氯化铝对某些苯基醚的作用

  摘要：

  DOI：

  10.1039/jr9440000330

文献信息

• [EN] COMPOUNDS THAT INDUCE FERROPTIC CELL DEATH<br/>[FR] COMPOSÉS INDUISANT LA MORT CELLULAIRE FERROPTOTIQUE
  申请人：UNIV ILLINOIS

  公开号：WO2020210158A1

  公开（公告）日：2020-10-15

  The diterpene natural product pleuromutilin was subjected to reaction sequences focused on creating ring system diversity in few synthetic steps. This effort resulted in a collection of compounds with previously unreported ring systems, providing a novel set of structurally diverse and highly complex compounds suitable for screening in a variety of different settings. Biological evaluation identified the novel compound ferroptocide, a small molecule that rapidly and robustly induces ferroptotic death of cancer cells. Target identification efforts and CRISPR knockout studies reveal that ferroptocide is an inhibitor of thioredoxin, a key component of the antioxidant system in the cell. Ferroptocide positively modulates the immune system in a murine model of breast cancer and will be a useful tool to study the utility of pro-ferroptotic agents for treatment of cancer.

  二萜类天然产物截短侧耳素经过一系列旨在通过少数合成步骤创造环系多样性的反应序列处理。这一努力产生了一批具有先前未报道环系的化合物，提供了一套结构多样且高度复杂的新化合物，适合在各种不同环境中进行筛选。生物学评估发现了一种新型化合物铁死亡素，这是一种小分子，能迅速且强有力地诱导癌细胞发生铁死亡。目标识别努力和CRISPR敲除研究表明，铁死亡素是一种硫氧还蛋白抑制剂，这是细胞抗氧化系统的一个关键组成部分。铁死亡素在乳腺癌的小鼠模型中正向调节免疫系统，并将成为研究促进铁死亡剂治疗癌症效用的有用工具。
• [EN] ANILINOPYRIMIDINES AS HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS<br/>[FR] ANILINOPYRIMIDINES EN TANT QU'INHIBITEURS DE KINASE 1 PROGÉNITRICES HÉMATOPOÏÉTIQUES (HPK1)
  申请人：ARIAD PHARMA INC

  公开号：WO2018102366A1

  公开（公告）日：2018-06-07

  The invention relates to HPK1 inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: where A, R1, R2, R3, R4, R5, R6, R16, R17, X1, X2, X3, X4, m, and n are described herein.

  这项发明涉及用于治疗癌症和其他丝氨酸-苏氨酸激酶介导的疾病的HPK1抑制剂，其化学式为：其中A、R1、R2、R3、R4、R5、R6、R16、R17、X1、X2、X3、X4、m和n如本文所述。
• CCR2 INHIBITORS AND METHODS OF USE THEREOF
  申请人：Basak Arindrajit

  公开号：US20100234364A1

  公开（公告）日：2010-09-16

  Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists, and as controls in assays for the identification of CCR9 antagonists.

  提供了作为CCR2或CCR9受体强效拮抗剂的化合物。动物实验表明，这些化合物对于治疗炎症非常有效，而炎症是CCR2和CCR9的典型疾病。这些化合物通常是芳基磺酰胺衍生物，在制药组合物、治疗CCR2介导疾病的方法、治疗CCR9介导疾病的方法、作为CCR2拮抗剂鉴定的检测中的对照物，以及作为CCR9拮抗剂鉴定的检测中的对照物中非常有用。
• [EN] 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES<br/>[FR] COMPOSÉS DE 2-PYRIDAZIN-3(2H)-ONE À SUBSTITUTION 2-ARYLE ET 2-HÉTÉROARYLE UTILISÉS EN TANT QU'INHIBITEURS DE FGFR TYROSINE KINASES
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2017070708A1

  公开（公告）日：2017-04-27

  Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

  本文提供了一般式I的化合物及其立体异构体和药学上可接受的盐或溶剂，其中X、R1、R2、R3、环A和z的含义如规范中所述，这些化合物是FGFR1、FGFR2、FGFR3和/或FGFR4的抑制剂，可用于治疗和预防可以用FGFR抑制剂治疗的疾病，包括由FGFR1、FGFR2、FGFR3和/或FGFR4介导的疾病或障碍。
• Triazine derivatives as inhibitors of phosphodiesterases
  申请人：Stange Hans

  公开号：US20100120762A1

  公开（公告）日：2010-05-13

  The invention relates to triazine derivatives of formula (I): which are inhibitors of phosphodiesterase 2 or 10, useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type 2 diabetes, metabolic syndrome, glucose intolerance, and pain.

  该发明涉及式（I）的三嗪衍生物，它们是磷酸二酯酶2或10的抑制剂，可用于治疗中枢神经系统疾病，如精神病，并且还可用于治疗例如肥胖症、2型糖尿病、代谢综合征、葡萄糖耐受不良和疼痛。